155 related articles for article (PubMed ID: 26392103)
41. Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma.
Querfeld C; Kuzel TM; Kim YH; Porcu P; Duvic M; Musiek A; Rook AH; Mark LA; Pinter-Brown L; Hamid O; Lin B; Bian Y; Boye M; Day JM; Rosen ST
Leuk Lymphoma; 2011 Aug; 52(8):1474-80. PubMed ID: 21649541
[TBL] [Abstract][Full Text] [Related]
42. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.
Talpur R; Jones DM; Alencar AJ; Apisarnthanarax N; Herne KL; Yang Y; Duvic M
J Invest Dermatol; 2006 Mar; 126(3):575-83. PubMed ID: 16410787
[TBL] [Abstract][Full Text] [Related]
43. Childhood mycosis fungoides with a CD8+ CD56+ cytotoxic immunophenotype.
Poppe H; Kerstan A; Böckers M; Goebeler M; Geissinger E; Rosenwald A; Hamm H
J Cutan Pathol; 2015 Apr; 42(4):258-64. PubMed ID: 25442255
[TBL] [Abstract][Full Text] [Related]
44. Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome.
Kohn EC; Steis RG; Sausville EA; Veach SR; Stocker JL; Phelps R; Franco S; Longo DL; Bunn PA; Ihde DC
J Clin Oncol; 1990 Jan; 8(1):155-60. PubMed ID: 2295906
[TBL] [Abstract][Full Text] [Related]
45. Other Chemotherapeutic Agents in Cutaneous T-Cell Lymphoma.
Chung CG; Poligone B
Dermatol Clin; 2015 Oct; 33(4):787-805. PubMed ID: 26433850
[TBL] [Abstract][Full Text] [Related]
46. Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome.
Foss FM; Ihde DC; Linnoila IR; Fischmann AB; Schechter GP; Cotelingam JD; Steinberg SM; Ghosh BC; Stocker JL; Bastian A
J Clin Oncol; 1994 Oct; 12(10):2051-9. PubMed ID: 7931473
[TBL] [Abstract][Full Text] [Related]
47. Complete resolution of mycosis fungoides tumors with imiquimod 5% cream: a case series.
Lewis DJ; Byekova YA; Emge DA; Duvic M
J Dermatolog Treat; 2017 Sep; 28(6):567-569. PubMed ID: 28635518
[TBL] [Abstract][Full Text] [Related]
48. Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents.
Devata S; Wilcox RA
Am J Clin Dermatol; 2016 Jun; 17(3):225-37. PubMed ID: 26923912
[TBL] [Abstract][Full Text] [Related]
49. Topical imiquimod as treatment for different kinds of cutaneous lymphoma.
Coors EA; Schuler G; Von Den Driesch P
Eur J Dermatol; 2006; 16(4):391-3. PubMed ID: 16935796
[TBL] [Abstract][Full Text] [Related]
50. Expression of CD31 in Mycosis Fungoides.
Jankowska-Konsur A; Kobierzycki C; Grzegrzolka J; Piotrowska A; Gomulkiewicz A; Glatzel-Plucinska N; Olbromski M; Podhorska-Okolow M; Szepietowski JC; Dziegiel P
Anticancer Res; 2016 Sep; 36(9):4575-82. PubMed ID: 27630298
[TBL] [Abstract][Full Text] [Related]
51. Transient CD30+ nodal transformation of cutaneous T-cell lymphoma associated with cyclosporine treatment.
Pielop JA; Jones D; Duvic M
Int J Dermatol; 2001 Aug; 40(8):505-11. PubMed ID: 11703521
[TBL] [Abstract][Full Text] [Related]
52. New and established treatment options for mycosis fungoides and Sézary syndrome - an update.
Dugas-Breit S; Schulze HJ; Hallermann C
J Dtsch Dermatol Ges; 2014 Jul; 12(7):561-9. PubMed ID: 24889480
[TBL] [Abstract][Full Text] [Related]
53. Therapeutic Update: Update on Cutaneous and Systemic Therapy for Primary Cutaneous T Cell Lymphoma, Mycosis Fungoides.
Lo Sicco K; Latkowski JA
J Drugs Dermatol; 2015 Dec; 14(12):1381-3. PubMed ID: 26659928
[No Abstract] [Full Text] [Related]
54. A rare presentation of erythrodermic mycosis fungoides.
Goyal T; Varshney A
Cutis; 2012 May; 89(5):229-32, 236. PubMed ID: 22768436
[TBL] [Abstract][Full Text] [Related]
55. Targeted therapies for cutaneous T-cell lymphomas.
Kaplan JB; Guitart J; Giles FJ
Expert Rev Hematol; 2014 Aug; 7(4):481-93. PubMed ID: 25025372
[TBL] [Abstract][Full Text] [Related]
56. CD30-rich transformed mycosis fungoides or anaplastic large cell lymphoma? How to get it right.
Kadin ME
Br J Dermatol; 2015 Jun; 172(6):1478-1479. PubMed ID: 26036155
[No Abstract] [Full Text] [Related]
57. Combination of etoposide, idarubicin, cyclophosphamide, vincristine, prednisone and bleomycin (VICOP-B) in the treatment of advanced cutaneous T-cell lymphoma.
Fierro MT; Doveil GC; Quaglino P; Savoia P; Verrone A; Bernengo MG
Dermatology; 1997; 194(3):268-72. PubMed ID: 9187846
[TBL] [Abstract][Full Text] [Related]
58. In vitro and in vivo effects of photodynamic therapy in cutaneous T cell lymphoma.
Boehncke WH; König K; Rück A; Kaufmann R; Sterry W
Acta Derm Venereol; 1994 May; 74(3):201-5. PubMed ID: 7915462
[TBL] [Abstract][Full Text] [Related]
59. Interferon and low dose methotrexate improve outcome in refractory mycosis fungoides/Sézary syndrome.
Avilés A; Nambo MJ; Neri N; Castañeda C; Cleto S; Gonzalez M; Huerta-Guzmán J
Cancer Biother Radiopharm; 2007 Dec; 22(6):836-40. PubMed ID: 18158775
[TBL] [Abstract][Full Text] [Related]
60. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?
Scarisbrick JJ; Kim YH; Whittaker SJ; Wood GS; Vermeer MH; Prince HM; Quaglino P
Br J Dermatol; 2014 Jun; 170(6):1226-36. PubMed ID: 24641480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]